보고서 요약(국문)

시장 개요
전 세계 신경내분비종양 치료 시장은 2022년 50억 5,320만 달러에 달했으며, 2030년까지 103억 9,870만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 신경내분비종양 치료 시장은 예측 기간(2023~2030년) 동안 연평균 9.7%의 성장률을 기록할 것으로 예상됩니다. 주요 시장 참여 기업들은 제품 범위 확대 및 제품 포트폴리오 강화를 위해 인수합병, 제품 승인, 계약 체결 등 다양한 전략을 통해 신경내분비종양 치료 시장 진출 및 경쟁력 강화를 도모하고 있습니다.

예를 들어, 2022년 9월 21일, 일라이 릴리 앤 컴퍼니는 미국 식품의약국(FDA)이 국소 진행성 또는 전이성 고형암을 앓고 있는 성인 환자 중 RET(rearranged during transfection) 유전자 융합 변이가 있는 환자, 그리고 이전에 전신 치료를 받았거나 그 후 질병이 진행되었거나 만족스러운 대체 치료 옵션이 없는 환자를 대상으로 레테브모(셀퍼카티닙, 40mg 및 80mg 캡슐)를 승인했다고 발표했습니다. 이 적응증은 객관적 반응률(ORR) 및 반응 지속 기간(DOR)을 기반으로 신속 승인 절차를 통해 승인되었습니다. 이 적응증에 대한 지속적인 승인은 확증 임상시험에서 임상적 유익성을 검증하고 설명하는 것에 따라 달라질 수 있습니다.
신경내분비종양 발병 사례 증가, 제품 승인 증가, 연구 확대 및 인식 제고는 전 세계 신경내분비종양 치료 시장 성장을 이끄는 요인입니다.
시장 동향
임상 연구 건수 증가가 전 세계 신경내분비종양 치료 시장 성장을 견인하고 있습니다.

신경내분비종양 치료를 위한 임상 연구가 증가함에 따라 전 세계 신경내분비종양 치료 시장이 성장하고 있습니다. 예를 들어, 2022년 9월 미국 국립암연구소(NCI)에서 발표한 새로운 연구에 따르면, NIH 임상센터에서 진행된 1/2상 임상 시험에서는 수술이 불가능하거나 전이성 신경내분비종양을 표적으로 삼아 상호 보완적으로 작용할 수 있는 두 가지 약물의 병용 요법의 효능을 평가했습니다. 한 가지 약물인 루타테라는 체내에 방사선을 조사하여 DNA 손상을 유도하고, 다른 약물인 올라파립은 PARP 억제제로 DNA 손상 복구를 차단합니다.
정부의 지원 및 자금 증가로 전 세계 신경내분비종양 치료 시장 성장 기회 확대
정부의 지원 및 자금 증가는 향후 몇 년 동안 전 세계 신경내분비종양 치료 시장에 유망한 성장 기회를 제공하고 있습니다. 예를 들어, 2022년 1월 호주 연방 보건부는 2021년 희귀암, 희귀질환 및 미충족 의료 수요(RCRDUN) 기금 지원 계획에 따라 희귀질환 및 희귀암 연구에 6,340만 달러의 보조금을 지원했습니다.
COVID-19 영향 분석
COVID-19 분석에는 COVID-19 이전 시나리오, COVID-19 시나리오, COVID-19 이후 시나리오와 함께 가격 변동(팬데믹 기간 및 이후의 가격 변화를 COVID-19 이전 시나리오와 비교), 수요-공급 양상(거래 제한, 봉쇄 및 그로 인한 문제로 인한 수요와 공급의 변화), 정부 정책(정부 기관의 시장, 부문 또는 산업 활성화 정책) 및 제조업체의 전략적 조치(제조업체가 COVID-19 관련 문제를 완화하기 위해 취한 조치)가 포함됩니다.

러시아-우크라이나 분쟁 분석
2022년 2월 24일 러시아 연방의 우크라이나 침공은 약 1,200만 명의 주민들이 집을 떠나 피난처를 찾는 대규모 이주 사태를 초래했습니다. 이 중 700만 명 이상이 우크라이나 내륙 지역으로 이주했고, 500만 명은 인접 국가로 피난했습니다. 이러한 상황은 해당 지역 시장 성장에 악영향을 미쳐 세계 시장 성장에도 부정적인 영향을 미쳤습니다.
글로벌 경기 침체 영향 분석
의료 산업 역시 경기 침체의 영향을 완전히 피할 수는 없습니다. 과거 경기 침체기에는 의료기관들이 인력 감축과 해고를 경험하기도 했습니다. 하지만 의료 산업은 필수적인 특성 덕분에 다른 산업에 비해 상대적으로 잘 대처하는 편입니다. 그럼에도 불구하고 인플레이션이 지속적으로 상승하면서 경기 침체에 대한 우려가 커지고 있습니다.
인공지능 영향 분석
암 진단, 신약 개발, 정밀 의학 분야에서 인공지능과 머신러닝을 활용하여 치료 수준과 환자 경험을 개선하는 것은 향후 전 세계 신경내분비 종양 치료 시장에 긍정적인 영향을 미칠 것으로 예상됩니다.
세그먼트 분석
전 세계 신경내분비종양 치료 시장은 치료 유형, 적응증, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.
췌장 신경내분비종양 부문은 2030년까지 전 세계 시장의 20%를 차지할 것으로 예상됩니다.
췌장 신경내분비종양에 대한 연구가 증가함에 따라, 이 부문은 2030년까지 전체 신경내분비종양 치료 시장의 약 20%를 차지할 것으로 예상됩니다. 예를 들어, 노스웨스턴 대학교에서 발표한 기사에 따르면, 두 가지 항암제를 병용하는 치료법이 진행성 췌장 신경내분비종양 환자의 치료 반응과 무진행 생존 기간을 향상시켰습니다.
지역 분석
유럽은 예측 기간 동안 전 세계 신경내분비종양 치료 시장에서 두 번째로 큰 시장 점유율을 차지할 것으로 예상됩니다.
유럽은 이 지역의 시장 발전으로 인해 전체 신경내분비종양 치료 시장의 약 28.7%를 차지할 것으로 예상됩니다. 예를 들어, 2021년 4월 독일의 비상장 생명공학 및 방사성 의약품 그룹인 ITM(Isotopen Technologien München)은 정밀 종양학 파이프라인을 발전시키고 신경내분비암 프로그램의 후기 개발에 자금을 지원하기 위해 1억 900만 달러 규모의 대출 투자를 유치했습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer, Inc., Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals, Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc. 및 Sanofi 등이 있습니다.
보고서 구매 이유

• 치료 유형, 적응증, 투여 경로, 최종 사용자 및 지역별 글로벌 신경내분비 종양 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위함입니다. • 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 신경내분비종양 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 신경내분비종양 치료 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global neuroendocrine tumor treatment market reached USD 5,053.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 10,398.7 million by 2030. The neuroendocrine tumor treatment market is expected to exhibit a CAGR of 9.7% during the forecast period (2023-2030). The key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the neuroendocrine tumor treatment market.
For instance, on September 21, 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on ORR and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
The growing cases of neuroendocrine tumors, increasing product approvals, growing research, and increasing awareness are the factors driving global neuroendocrine tumor treatment market growth.
Market Dynamics
The Increasing Number of Clinical Research is Driving the Global Neuroendocrine Tumor Treatment Market Growth.
The growing number of clinical research for the treatment of neuroendocrine tumors is driving the global neuroendocrine tumor treatment market growth. For instance, according to a new published by National Cancer Institute in September 2022, a phase I/II clinical trial at the NIH Clinical Center assesses the efficacy of a mixture of two medications that may function in complementary manners to target inoperable or metastatic neuroendocrine tumors. One agent, lutathera, radiates radiation inside the body, inducing DNA damage, and the second agent, olaparib, a PARP inhibitor, stops the restoration of DNA breaks.
The Increasing Government Initiatives and Funding Provide Growth Opportunities to the Global Neuroendocrine Tumor Treatment Market
The increasing government funding and initiatives are presenting the global neuroendocrine tumor treatment market with prospective growth opportunities in the upcoming years. For instance, in January 2022, the Department of Health of the Commonwealth of Australia provided a grant of USD 63.4 million for the rare diseases and rare cancers investigation in response to the 2021 Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) funding prospect.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine Conflict Analysis
The Russian Federation's invasion of Ukraine on February 24, 2022, generated a huge dislocation of the residents with an assessed 12 million individuals escaping their residences and scouring for protection. Over seven million individuals were internally replaced to additional regions of Ukraine, while five million fled to bordering nations. This has disturbed the market growth in this region thereby negatively impacting the global market growth.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession.
Artificial Intelligence Impact Analysis
The employment of artificial intelligence and machine learning in cancer diagnosis, drug development, and precision medicine in oncology to improve the treatment standard and patient experiences are positively impacting the global neuroendocrine tumor treatment market in the forecast period.
Segment Analysis
The global neuroendocrine tumor treatment market is segmented based on therapy type, indication, route of administration, end-user, and region.
The Pancreatic Neuroendocrine Tumor segment is Estimated to Hold a 20% Share of the Global Market by 2030.
Owing to the increasing research in the pancreatic neuroendocrine tumor, the segment is estimated to hold around 20% of the total neuroendocrine tumor treatment market by 2030. For instance, according to a news article published by Northwestern University, a blend therapy practice employing two chemotherapy medications enhanced therapy reaction and progression-free survival in individuals with advanced pancreatic neuroendocrine tumors.
Geographical Analysis
Europe is Estimated to Hold the Second-largest Global Neuroendocrine Tumor Treatment Market Share During the Forecast Period.
Europe is estimated to hold around 28.7% of the total neuroendocrine tumor treatment market owing to the market developments in this region. For instance, in April 2021, Germany’s ITM, or Isotopen Technologien München a privately held biotechnology and radiopharmaceutical group of corporations, secured a $109 million round of loan financing to advance its precision oncology pipeline and fund late-stage development for its neuroendocrine cancer program.
Competitive Landscape
The major global players in the market include Pfizer, Inc., Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals, Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc. and Sanofi among others.
Why Purchase the Report?
• To visualize the global neuroendocrine tumor treatment market segmentation based on therapy type, indication, route of administration, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of neuroendocrine tumor treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global neuroendocrine tumor treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by End User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Cases of Neuroendocrine Tumors.
4.1.1.2. Product Approvals.
4.1.1.3. Increase in Research Activities.
4.1.2. Restraints
4.1.2.1. Treatment Side Effects.
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. PEST Analysis
5.6. Pipeline Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine Conflict Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Therapy Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.1.2. Market Attractiveness Index, By Therapy Type
10.2. Somatostatin analogs (SSAs)
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Targeted therapy
10.4. Others
11. By Indication
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Gastrointestinal*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Lungs
11.4. Pancreas
11.5. Others
12. By Route of Administration
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Oral
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Injectable
13. By End User
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.1.2. Market Attractiveness Index, By End User
13.2. Hospitals
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Cancer Research Center
13.4. Ambulatory Surgery Centers
14. By Region
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
15. Competitive Landscape
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. Company Profiles
16.1. Pfizer, Inc.
16.1.1. Company Overview
16.1.2. Therapy Type Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. Ipsen Pharmaceuticals
16.3. Novartis
16.4. AVEO Pharmaceuticals, Inc.
16.5. Eli Lilly & Company
16.6. CK Hutchison Holdings (HUTCHMED)
16.7. C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH)
16.8. Lantheus Holdings, Inc.
16.9. Merck & Co., Inc.
16.10. Sanofi
LIST NOT EXHAUSTIVE
17. Appendix
17.1. About Us and Services
17.2. Contact Us

언급된 주요 기업들

Pfizer, Inc., 4.	Key Developments, Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals, Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc., Sanofi

표 목록 (Tables)

List of Tables

Table 1 Global Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2023, 2027 & 2031 (USD Million)

Table 2 Global Neuroendocrine Tumor Treatment Market Value, By Indication, 2023, 2027 & 2031 (USD Million)

Table 3 Global Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (USD Million)

Table 4 Global Neuroendocrine Tumor Treatment Market Value, By End User, 2023, 2027 & 2031 (USD Million)

Table 5 Global Neuroendocrine Tumor Treatment Market Value, By Region, 2023, 2027 & 2031 (USD Million)

Table 6 Global Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2023, 2027 & 2031 (USD Million)

Table 7 Global Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2022-2031 (USD Million)

Table 8 Global Neuroendocrine Tumor Treatment Market Value, By Indication, 2023, 2027 & 2031 (USD Million)

Table 9 Global Neuroendocrine Tumor Treatment Market Value, By Indication, 2022-2031 (USD Million)

Table 10 Global Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (USD Million)

Table 11 Global Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2022-2031 (USD Million)

Table 12 Global Neuroendocrine Tumor Treatment Market Value, By End User, 2023, 2027 & 2031 (USD Million)

Table 13 Global Neuroendocrine Tumor Treatment Market Value, By End User, 2022-2031 (USD Million)

Table 14 Global Neuroendocrine Tumor Treatment Market Value, By Region, 2023, 2027 & 2031 (USD Million)

Table 15 Global Neuroendocrine Tumor Treatment Market Value, By Region, 2022-2031 (USD Million)

Table 16 North America Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2022-2031 (USD Million)

Table 17 North America Neuroendocrine Tumor Treatment Market Value, By Indication, 2022-2031 (USD Million)

Table 18 North America Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2022-2031 (USD Million)

Table 19 North America Neuroendocrine Tumor Treatment Market Value, By End User, 2022-2031 (USD Million)

Table 20 North America Neuroendocrine Tumor Treatment Market Value, By Country, 2022-2031 (USD Million)

Table 21 South America Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2022-2031 (USD Million)

Table 22 South America Neuroendocrine Tumor Treatment Market Value, By Indication, 2022-2031 (USD Million)

Table 23 South America Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2022-2031 (USD Million)

Table 24 South America Neuroendocrine Tumor Treatment Market Value, By End User, 2022-2031 (USD Million)

Table 25 South America Neuroendocrine Tumor Treatment Market Value, By Country, 2022-2031 (USD Million)

Table 26 Europe Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2022-2031 (USD Million)

Table 27 Europe Neuroendocrine Tumor Treatment Market Value, By Indication, 2022-2031 (USD Million)

Table 28 Europe Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2022-2031 (USD Million)

Table 29 Europe Neuroendocrine Tumor Treatment Market Value, By End User, 2022-2031 (USD Million)

Table 30 Europe Neuroendocrine Tumor Treatment Market Value, By Country, 2022-2031 (USD Million)

Table 31 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2022-2031 (USD Million)

Table 32 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, By Indication, 2022-2031 (USD Million)

Table 33 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2022-2031 (USD Million)

Table 34 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, By End User, 2022-2031 (USD Million)

Table 35 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, By Country, 2022-2031 (USD Million)

Table 36 Middle East & Africa Neuroendocrine Tumor Treatment Market Value, By Therapy Type, 2022-2031 (USD Million)

Table 37 Middle East & Africa Neuroendocrine Tumor Treatment Market Value, By Indication, 2022-2031 (USD Million)

Table 38 Middle East & Africa Neuroendocrine Tumor Treatment Market Value, By Route of Administration, 2022-2031 (USD Million)

Table 39 Middle East & Africa Neuroendocrine Tumor Treatment Market Value, By End User, 2022-2031 (USD Million)

Table 40 Pfizer, Inc.: Overview

Table 41 Pfizer, Inc.: Product Portfolio

Table 42 Pfizer, Inc.: Key Developments

Table 43 Ipsen Pharmaceuticals: Overview

Table 44 Ipsen Pharmaceuticals: Product Portfolio

Table 45 Ipsen Pharmaceuticals: Key Developments

Table 46 Novartis: Overview

Table 47 Novartis: Product Portfolio

Table 48 Novartis: Key Developments

Table 49 AEO Pharmaceuticals, Inc.: Overview

Table 50 AEO Pharmaceuticals, Inc.: Product Portfolio

Table 51 AEO Pharmaceuticals, Inc.: Key Developments

Table 52 Eli Lilly & Company: Overview

Table 53 Eli Lilly & Company: Product Portfolio

Table 54 Eli Lilly & Company: Key Developments

Table 55 CK Hutchison Holdings (HUTCHMED): Overview

Table 56 CK Hutchison Holdings (HUTCHMED): Product Portfolio

Table 57 CK Hutchison Holdings (HUTCHMED): Key Developments

Table 58 C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH): Overview

Table 59 C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH): Product Portfolio

Table 60 C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH): Key Developments

Table 61 Lantheus Holdings, Inc.: Overview

Table 62 Lantheus Holdings, Inc.: Product Portfolio

Table 63 Lantheus Holdings, Inc.: Key Developments

Table 64 Merck & Co., Inc.: Overview

Table 65 Merck & Co., Inc.: Product Portfolio

Table 66 Merck & Co., Inc.: Key Developments

Table 67 Sanofi: Overview

Table 68 Sanofi: Product Portfolio

Table 69 Sanofi: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 2 Global Neuroendocrine Tumor Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 3 Global Neuroendocrine Tumor Treatment Market Share, By Indication, 2022 & 2031 (%)

Figure 4 Global Neuroendocrine Tumor Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 5 Global Neuroendocrine Tumor Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 6 Global Neuroendocrine Tumor Treatment Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Neuroendocrine Tumor Treatment Market Y-o-Y Growth, By Therapy Type, 2022-2030 (%)

Figure 8 Somatostatin analogs (SSAs) Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 9 Targeted therapy Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 10 Others Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 11 Global Neuroendocrine Tumor Treatment Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 13 Lungs Indication in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 14 Pancreas Indication in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 15 Gastrointestinal Indication in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 16 Others Indication in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 17 Global Neuroendocrine Tumor Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 18 Oral Route of Administration in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 19 Injectable Route of Administration in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 20 Global Neuroendocrine Tumor Treatment Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 21 Hospitals in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 22 Cancer Research Center End User in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 23 Ambulatory Surgery Centers in Global Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 24 Global Neuroendocrine Tumor Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 26 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 27 Europe Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 28 South America Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 29 Middle East and Africa Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 30 North America Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 31 North America Neuroendocrine Tumor Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 32 North America Neuroendocrine Tumor Treatment Market Share, By Indication, 2022 & 2031 (%)

Figure 33 North America Neuroendocrine Tumor Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 34 North America Neuroendocrine Tumor Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 35 North America Neuroendocrine Tumor Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 36 South America Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 37 South America Neuroendocrine Tumor Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 38 South America Neuroendocrine Tumor Treatment Market Share, By Indication, 2022 & 2031 (%)

Figure 39 South America Neuroendocrine Tumor Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 40 South America Neuroendocrine Tumor Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 41 South America Neuroendocrine Tumor Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 42 Europe Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 43 Europe Neuroendocrine Tumor Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 44 Europe Neuroendocrine Tumor Treatment Market Share, By Indication, 2022 & 2031 (%)

Figure 45 Europe Neuroendocrine Tumor Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 46 Europe Neuroendocrine Tumor Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 47 Europe Neuroendocrine Tumor Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 48 Asia-Pacific Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 49 Asia-Pacific Neuroendocrine Tumor Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 50 Asia-Pacific Neuroendocrine Tumor Treatment Market Share, By Indication, 2022 & 2031 (%)

Figure 51 Asia-Pacific Neuroendocrine Tumor Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 52 Asia-Pacific Neuroendocrine Tumor Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 53 Asia-Pacific Neuroendocrine Tumor Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 54 Middle East & Africa Neuroendocrine Tumor Treatment Market Value, 2022-2031 (USD Million)

Figure 55 Middle East & Africa Neuroendocrine Tumor Treatment Market Share, By Therapy Type, 2022 & 2031 (%)

Figure 56 Middle East & Africa Neuroendocrine Tumor Treatment Market Share, By Indication, 2022 & 2031 (%)

Figure 57 Middle East & Africa Neuroendocrine Tumor Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 58 Middle East & Africa Neuroendocrine Tumor Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 59 Pfizer, Inc.: Financials

Figure 60 Ipsen Pharmaceuticals: Financials

Figure 61 Novartis: Financials

Figure 62 AEO Pharmaceuticals, Inc.: Financials

Figure 63 Eli Lilly & Company: Financials

Figure 64 CK Hutchison Holdings (HUTCHMED): Financials

Figure 65 C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH): Financials

Figure 66 Lantheus Holdings, Inc.: Financials

Figure 67 Merck & Co., Inc.: Financials

Figure 68 Sanofi: Financials

글로벌 신경내분비종양 치료 시장 – 2023-2030

Global Neuroendocrine Tumor Treatment Market - 2023-2030